Seattle Genetics, Inc. Presents Data from Phase 1 Clinical Trial Of Antibody-Drug Conjugate (ADC) SGN-CD19A In Non-Hodgkin Lymphoma At American Society of Clinical Oncology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) today will present interim phase 1 clinical data from SGN-CD19A, an antibody-drug conjugate (ADC) in development for the treatment of B-cell malignancies, at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting being held May 30 to June 3, 2014 in Chicago, IL. SGN-CD19A is an ADC targeting CD19, a protein expressed on B-cell malignancies.

Help employers find you! Check out all the jobs and post your resume.